Perrigo attributes flat second quarter sales to slow start to cough/cold season.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO SECOND QUARTER SALES FLAT AT $174.7 MIL. due to a slow start to the cough/cold season, the company said in a Feb. 7 release. "The second quarter was a difficult period for our company due to a very weak start to the cough and cold season this year, which negatively impacted sales of our largest product categories," Perrigo said. As a result, the firm explained, sales of cold remedies have been "below expectations.